DE60323107D1 - Behandlungs methode und lösung zur hemmung der trübung der hinteren kapsel - Google Patents

Behandlungs methode und lösung zur hemmung der trübung der hinteren kapsel

Info

Publication number
DE60323107D1
DE60323107D1 DE60323107T DE60323107T DE60323107D1 DE 60323107 D1 DE60323107 D1 DE 60323107D1 DE 60323107 T DE60323107 T DE 60323107T DE 60323107 T DE60323107 T DE 60323107T DE 60323107 D1 DE60323107 D1 DE 60323107D1
Authority
DE
Germany
Prior art keywords
agent
treatment solution
cells
treatment
epithelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323107T
Other languages
English (en)
Inventor
Jin Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60323107D1 publication Critical patent/DE60323107D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE60323107T 2002-09-17 2003-08-28 Behandlungs methode und lösung zur hemmung der trübung der hinteren kapsel Expired - Lifetime DE60323107D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/244,878 US7985405B2 (en) 2002-09-17 2002-09-17 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
PCT/IB2003/003600 WO2004026288A1 (en) 2002-09-17 2003-08-28 A treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells

Publications (1)

Publication Number Publication Date
DE60323107D1 true DE60323107D1 (de) 2008-10-02

Family

ID=31991988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323107T Expired - Lifetime DE60323107D1 (de) 2002-09-17 2003-08-28 Behandlungs methode und lösung zur hemmung der trübung der hinteren kapsel

Country Status (10)

Country Link
US (2) US7985405B2 (de)
EP (1) EP1542663B1 (de)
JP (1) JP4502811B2 (de)
CN (1) CN1700909B (de)
AT (1) ATE405255T1 (de)
AU (1) AU2003250495B2 (de)
CA (1) CA2499195C (de)
DE (1) DE60323107D1 (de)
HK (1) HK1085130A1 (de)
WO (1) WO2004026288A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985405B2 (en) 2002-09-17 2011-07-26 Jin Jun Zhang Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
US7875270B2 (en) * 2002-09-17 2011-01-25 Abbott Medical Optics Inc. Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
US20080039416A1 (en) * 2004-06-02 2008-02-14 Ho Steffan N Methods for Treating Disease by Modulating an Osmotic Stress Pathway
GB0419145D0 (en) * 2004-08-27 2004-09-29 Univ Dundee Treatment of posterior capsule opacification
US20060209253A1 (en) * 2004-10-20 2006-09-21 Giles Brian C Method and composition for eliminating ocular hypoxic acidosis
WO2006089288A2 (en) * 2005-02-19 2006-08-24 Lenticular Research Group Llc Apparatus and processes for preventing or delaying onset or progression of age-related cataract
US20120083772A1 (en) * 2010-09-30 2012-04-05 Curveright Llc Corneal treatment system and method
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
CN102526103B (zh) * 2010-12-07 2013-11-13 西藏海思科药业集团股份有限公司 一种多种微量元素注射液药物组合物及其制备方法
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
EP2830554A1 (de) 2012-03-29 2015-02-04 CXL Ophthalmics, LLC Okulares vernetzungssystem und verfahren zum verschliessen von wunden in der augenhornhaut
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
CN106986876B (zh) * 2017-03-20 2019-02-19 北京理工大学 一种靶向标记眼晶体上皮细胞的荧光探针、其制备及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3241765A1 (de) 1982-11-11 1984-05-17 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin Stabile zubereitungen fuer injektionszwecke enthaltend hydrochlorothiazid
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1990009792A1 (en) * 1989-03-03 1990-09-07 The General Hospital Corporation Topical application of amiloride or analogues thereof for treatment of inflammation
DE69535673D1 (de) 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
EP1250924A4 (de) * 2000-01-26 2007-03-14 Kyorin Seiyaku Kk Augentropfen
WO2003026744A1 (en) 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
US7985405B2 (en) 2002-09-17 2011-07-26 Jin Jun Zhang Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
SE0202924D0 (sv) 2002-10-03 2002-10-03 Pharmacia Groningen Bv Compositions for preventing posterior capsular opacification and the use therefor

Also Published As

Publication number Publication date
WO2004026288A1 (en) 2004-04-01
CN1700909A (zh) 2005-11-23
JP2006507252A (ja) 2006-03-02
US8114432B2 (en) 2012-02-14
AU2003250495B2 (en) 2009-06-04
CA2499195A1 (en) 2004-04-01
US20070129286A1 (en) 2007-06-07
US7985405B2 (en) 2011-07-26
AU2003250495A1 (en) 2004-04-08
JP4502811B2 (ja) 2010-07-14
EP1542663A1 (de) 2005-06-22
US20040052823A1 (en) 2004-03-18
ATE405255T1 (de) 2008-09-15
EP1542663B1 (de) 2008-08-20
CA2499195C (en) 2011-05-24
CN1700909B (zh) 2011-05-18
HK1085130A1 (en) 2006-08-18

Similar Documents

Publication Publication Date Title
HK1085130A1 (en) A treatment solution and use for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
Barros et al. The use of xenologous amniotic membrane to repair canine corneal perforation created by penetrating keratectomy
De Young et al. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model
Brummer et al. The role of nonenzymatic glycation and carbonyls in collagen cross-linking for the treatment of keratoconus
TW200719827A (en) Composition and method for in vitro preservation of corneal tissues
DK199801679A (da) Præparat samt kit til brug ved intraoculære operationer
Arafat et al. UV cross-linking of donor corneas confers resistance to keratolysis
KR20040078663A (ko) 난청의 치료 방법
Tang et al. ACS6, a Hydrogen sulfide-donating derivative of sildenafil, inhibits homocysteine-induced apoptosis by preservation of mitochondrial function
DK1023077T3 (da) Ophthalmisk sammensætning
CY1111335T1 (el) Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης
EP2269576A3 (de) Behandlungslösung und Verfahren zur Prävention von Trübungen der hinteren Kapsel durch selektive Induktion der Ablösung und/oder des Absterbens von Epithelzellen in der Linse
Duncan et al. Lens cell survival after exposure to stress in the closed capsular bag
Yao et al. Why is rose bengal more phototoxic to fibroblasts in vitro than in vivo?
Riley et al. Glutathione in the aqueous humor of human and other species.
Koc et al. The protective role of erdosteine on testicular tissue after testicular torsion and detorsion
Nicosia et al. Effects of vasoactive intestinal polypeptide (VIP) in human prolactin (PRL) secreting pituitary adenomas: Stimulation of PRL release and activation of adenylate cyclase
Günay et al. Evaluation of autologous serum eyedrops for the treatment of experimentally induced corneal alcali burns
Halestrap The mitochondrial permeability transition-a pore way for the heart to die
BRPI0606932A2 (pt) formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação
Shetty Evaluation of Echitamine, Ditamine and Echitenine for Anticataract Activity using in vitro cataract Model
RU2678966C1 (ru) Способ повышения биосовместимости перикардиальных биоматериалов для реконструктивной хирургии
RU2291675C2 (ru) Способ обработки трансплантатов для сердечно-сосудистой хирургии
Hong et al. Comment on phakic descemet stripping automated endothelial keratoplasty: prevalence and prognostic impact of postoperative cataracts
WO1999039722A3 (en) Compositions and methods for separating lens epithelial cells and preventing posterior capsular opacification

Legal Events

Date Code Title Description
8364 No opposition during term of opposition